Waiving patents alone won't solve COVID-19 vaccine access - developers


FILE PHOTO: A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo

GENEVA (Reuters) - Waiving intellectual property rights will not be enough to resolve COVID-19 vaccine access issues, the developers of the Oxford/Astrazeneca and the Pfizer/BioNTech vaccines said on Monday, ahead of a meeting on the topic at the World Trade Organization this week.

"I don't think just making IP fully available goes anywhere close to solving the problem...," said the University of Oxford professor Sarah Gilbert at a World Health Organization virtual press conference.

BioNTech's Chief Medical Officer Dr Özlem Türeci said at the same briefing: "Patents are one thing, but there are so many other things we have to ensure."

(Reporting by Emma Farge, Silke Koltrowitz and Toby Chopra; Editing by Hugh Lawson)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
   

Next In World

Biden says Putin right that US-Russian relations are at low point
G7 demand action from Russia on cybercrimes and chemical weapon use
Erdogan says he and Biden must leave troubles behind at NATO meeting
Weaknesses in US healthcare system leaves ethnic minorities, essential workers exposed, says report
Thousands protest against Spain's possible pardons for jailed Catalan leaders
Dutch political gridlock deepens as key lawmaker quits Christian Democrat party
Ambush in northern Ivory Coast kills three soldiers
Swiss voters look set to reject law to help cut carbon emissions
G7's billion vaccine plan counts some past pledges, limiting impact
S.Africa's President Ramaphosa urges G7 nations to plug COVID-19 funding gap

Stories You'll Enjoy


Vouchers